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doi:10.1016/j.jmii.2012.05.008Background: CD14 is expressed principally by cells of monocyte/macrophage lineage and plays
a pivotal role in the innate immunity to intracellular infections. Recent research findings have
revealed an association between the CD14 gene promoter polymorphism and several major
infectious diseases.
Objective: The aim of the present study was to investigate the association between the
CD14-159C/T polymorphism and tuberculosis in a Turkish population.
Methods: For this purpose, 88 consecutive patients with tuberculosis (63 pulmonary, 25 extra-
pulmonary) and 116 control subjects were enrolled into a prospective study. We determined
CD14-159 genotypes by polymerase chain reaction - restriction fragment length polymorphism
analysis and also measured serum concentrations of soluble CD14 (sCD14) by using a quantita-
tive sandwich enzyme immunoassay technique.
Results: There was no significant difference in terms of genotype distribution between
patients with tuberculosis (CC 18.2%, CT 48.9%, TT 33.0%) and controls (CC 12.9%, CT 50.9%,
TT 36.2%) or between patients with pulmonary and extrapulmonary tuberculosis. Serum levels
of sCD14 were significantly increased in patients with active tuberculosis compared to those
with inactive tuberculosis and healthy controls (p< 0.001). However, levels of sCD14 were
not associated with any genotypes of CD14-159.
Conclusion: The genotyping findings of the present study do not support a role for the
CD14-159C/T polymorphism in the development of tuberculosis, at least in the geographicalk. 32/3, Dikmen, PO Box 06460, Ankara, Turkey.
(E. Ayaslioglu).
an Society of Microbiology. Published by Elsevier Taiwan LLC. All rights reserved.
CD14 gene promoter polymorphism and tuberculosis 159region of central Anatolia. Significantly elevated serum sCD14 levels in patients with active
disease reflect the importance of the mononuclear phagocytic system activation in tubercu-
losis.
Copyright ª 2012, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Activation of macrophages represents one of the initial
events in the innate immunity to intracellular infections.
CD14 is expressed principally by cells of monocyte/macro-
phage lineage and plays a pivotal role in the innate
recognition of bacterial cell wall components. The binding of
a microbial component to CD14, as an accessory receptor for
toll-like receptor (TLR), results in cellular activation and
initiates a variety of effector functions including cytokine
secretion and proliferation.1e3 CD14 exists in both
membrane-bound and soluble forms. Soluble CD14 (sCD14) is
present in the circulation and other body fluids, and its levels
in plasma increase during inflammation and infection.4,5
Exposure toMycobacterium tuberculosis (M tuberculosis)
can result in numerous different clinical outcomes. Only
about 25% of those exposed to M tuberculosis become
infected. While most infections result in a latent infection,
a minority of these cases eventually progresses to active
disease. Active tuberculosis may manifest a broad spectrum
of clinical presentations varying from lung involvement
to dissemination of the disease and multiorgan
involvement.6e9 Host genetic factors play a major role in
determining differential susceptibility to major infectious
diseases.9,10 Genetic polymorphisms in the immune response
to M tuberculosis may explain interindividual differences in
both susceptibility to disease and the course of infection.
Innate immune receptors and recognition of bacterial
products play a central role in the immune response to
infectious organisms. Polymorphisms involving these innate
immune receptors and related molecules, have been
described to be associated with susceptibility to infectious
diseases.3,11e14 A possible relationship between CD14-
159C/T polymorphism and several infections such as
brucellosis, sepsis, chronic Chlamydia pneumoniae infec-
tion, and bacterial diarrhea, has been implicated previ-
ously.11,12,15,16 The impact of the CD14-159C/T
polymorphism on the susceptibility to tuberculosis has
also been examined in several studies, providing contro-
versial results among the different populations.3,17,18 The
aim of the present study was to analyze the association
between the CD14-159C/T polymorphism and tuberculosis
in a Turkish population.Methods
Subjects
This prospective study included 88 unrelated tuberculosis
patients from central Anatolia who presented to the
Infectious Diseases and Clinical Microbiology Department ofKırıkkale University Faculty of Medicine, or were admitted
to the Ataturk Chest Disease and Surgery Center, Depart-
ment of Respiratory Medicine, between September 2008
and March 2010. It was approved by the ethical committees
of these two hospitals, and written informed consent was
obtained from the study participants.
The inclusion criteria were as follows: (1) having a diag-
nosis of tuberculosis; (2) age  16 years; and (3) consented
to be included into the study. The healthy group consisted
of subjects with no known diseases. The exclusion criteria
for both patient and healthy groups were: (1) having any
infectious diseases other than tuberculosis in the last 6
weeks; (2) having significant chronic systemic diseases
which could lead to immunosuppression; (3) being preg-
nant; and (4) being HIV positive (testing positive for HIV).
Pulmonary tuberculosis (nZ 63) group
There were 63 patients in this group. The diagnosis of
pulmonary tuberculosis was based on the presence of acid-
fast bacilli by sputum smear or M tuberculosis by culture of
sputum and bronchoalveolar lavage fluid. In patients with
negative smears and cultures, the diagnosis of tuberculosis
was based on symptoms, chest radiographic infiltrates in the
upper lobes, and clinical and radiographic responses to
antituberculosis drugs. The patients were divided radiologi-
cally into three categories according to the severity of the
pulmonary lesions, asminimal,moderate-advanced, and far-
advanced.19
Extrapulmonary tuberculosis (nZ 25) group
This study group included 25 cases of extrapulmonary
tuberculosis. Nine patients had pleural involvement; six of
them suffered from concomitant pulmonary tuberculosis,
whereas the other three patients had isolated pleural
involvement (tuberculous pleuritis). Four patients had
cervical and/or submandibular lymphadenitis, and two of
them were reported as recurrent lymphadenitis. Four
patients were diagnosed as urogenital tuberculosis (two
had renal involvement, two had epididymitis). Six patients
had tuberculous meningitis, with cranial nerve involvement
(2), osteoarticular involvement (2), mediastinitis (1), and
peritonitis (1). One patient was diagnosed with lupus vul-
garis involving the left upper eyelid, and the last case had
disseminated tuberculosis with splenic and scrotal
abscesses. The majority of extrapulmonary tuberculosis
cases (15) were diagnosed with histopathological exami-
nation of the pleura, lymph node, peritoneum, and bone
biopsy samples; culture was positive in eight cases with
extrapulmonary tuberculosis [tuberculous pleuritis (3),
lymphadenitis (3), peritonitis (1), and scrotal abscesses
Figure 1. Percentages of the genotypes (CC, TT, CT) in the
control and tuberculosis groups.
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five patients with negative culture and histopathological
examination was based on the presence of compatible
clinical findings in conjunction with radiological and labo-
ratory findings or response to antituberculosis drugs.
The patient group included both new and previously
diagnosedcasesof tuberculosis. Fifty-four patientshadnewly
diagnosed active tuberculosis andwereassigned as the active
tuberculosis group. Thirty-four patients were under antitu-
berculous treatment. After completion of the treatment,
theywere included into the study and assignedas the inactive
tuberculosis group. One hundred and sixteen healthy indi-
viduals (meanageZ 32.96 10.48 years,M/FZ 59/57)were
assignedas thecontrol group. Healthy subjectswere selected
from the adult population who had no underlying co-
morbidity and no diagnosis of tuberculosis. All subjects
were tested for tuberculin skin test (TST) with purified
protein derivative (PPD). Subjects with a recent history of
tuberculosis contact and a positive PPD were screened by
chest-x ray and sputum culture to exclude active disease.
Genotyping of CD14-159 polymorphism
Isolation of the genomic DNA from the peripheral blood
leukocytes was carried out by using phenol-chloroform
extraction and the ethanol precipitation method. Poly-
merase chain reaction (PCR) was carried out in a 25 mL
volume containing 100 ng of genomic DNA, 10 mM Tris-HCl
(pH 8.3), 50 mM KCl, 1.5 mM MgCl2, 200 mM of each deoxy-
nucleotide triphosphate, 1 unit of Taq DNA polymerase
(Promega,Madison,WI, USA), and 5 pmol of eachprimer. The
sequence of primers was as follows: Forward
5’-TAGATTCTCTGGGATATAAGG-3’ and Reverse 5’-CTGA-
CAGTTTATGTAATCCTG-3’. The DNA was denatured at 95C
for 5minutes, and cyclingwas set at 95C for 30 seconds, 56C
for 30 seconds, and 72C for 45 seconds for 35 cycles, fol-
lowed by a final extension at 72C for 5 minutes. Aliquots of
PCR products were digested with restriction endonuclease,
Eco47I (Ava II) (Fermentas Life Sciences, Vilnius, Lithuania)
at 37C. Digestion products were electrophoresed on 3%
agarose gels and visualized with ethidium-bromide staining
and ultraviolet illumination. The sizes of the generated
digestion products were 357 bp for CC allele, 357 bp-217 bp-
140 bp for heterozygotes and 217 bp-140 bp for TT allele.
Serum sCD14 measurement
Serum sCD14 levels were determined for 82 tuberculosis
patients and 99 normal controls using Quantikine kits
(Quantikine R&D Systems, Inc., Minneapolis, MN, USA). This
assay employs the quantitative sandwich enzyme immuno-
assay technique. All procedures were applied according to
manufacturer’s instruction.
Erythrocyte sedimentation rate (ESR) was measured by
Westergren’s method, and C-reactive protein (CRP) was
tested by immunoturbidimetric assay.
Statistical analysis
Statistical analysis was performed with the SPSS-16.0
statistical package. HardyeWeinberg equilibrium wastested with the Chi-square statistic. Comparisons of sCD14
levels between groups were made using univariate analysis
of variance (ANOVA) or analysis of covariance (ANCOVA),
using age and gender as covariates. Categorical variables
were compared by the Chi-square test. Spearman correla-
tion coefficient was performed to establish a correlation
between sCD14, CRP and ESR values. A p value < 0.05 was
considered significant.Results
This study included 88 consecutive patients with tubercu-
losis (63 pulmonary, 25 extrapulmonary). The mean age of
the patients was 49.93 16.15 years (rangeZ 16 to 78
years), and 65 (73.9%) were males. Genotyping was done in
all study populations and healthy controls. The distribution
of each of the genetic variants met the conditions of the
Hardy-Weinberg equilibrium.
There was no significant difference in the genotype
distributions between patients with tuberculosis (CC 18.2%,
CT 48.9%, TT 33.0%) and controls (CC 12.9%, CT 50.9%, TT
36.2%), or between patients with pulmonary and extrap-
ulmonary tuberculosis (Figs. 1 and 2). There was also no
association between allelic frequencies. About half of the
individuals in both groups were CT heterozygous.
The severity of the pulmonary lesions was graded in 73
patients, including patients with extrapulmonary tubercu-
losis with lung involvement. Far-advanced, moderate-
advanced and minimal involvement was detected in 31, 26
and 16 patients, respectively. The genotype frequencies
observed in these three groups were similar. The genotype
frequencies observed in patients with far-advanced
(CC 25.8%, CT 41.9%, TT 32.3%), moderate-advanced
(CC 11.5%, CT 57.7%, TT 30.8%), and minimal involvement
(CC 18.8%, CT 43.8%, TT 37.5%) were similar. No association
was found between CD14-159C/T polymorphism and the
severity of pulmonary involvement.
Serum sCD14 levels were determined for 80 tuberculosis
patients (49 active, 31 inactive) and 99 healthy controls.
Serum levels of sCD14 were significantly increased in
patients with active tuberculosis compared to those with
inactive tuberculosis and healthy controls (p< 0.001)
(Fig. 3).
Figure 2. Percentages of the genotypes (CC, TT, CT) in the
tuberculosis and extrapulmonary tuberculosis groups.
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with the levels of serum sCD14 in the tuberculosis patients
and controls was also tested. However, levels of sCD14
were not associated with any genotypes of CD14-159,
(CD14-159 TTZ 8.27 4.25 ug/mL, CD14-159 CTZ 8.21
4.13 ug/mL, CD14-159 CCZ 9.13 5.37 ug/mL).
ESR and CRP, markers of acute phase response, were
measured in patients with tuberculosis. Because sCD14 is
also regarded as an acute phase protein, a possible corre-
lation between the levels of serum sCD14, ESR and CRP
were investigated. The median levels of CRP and ESR were
2.65 (5.86) versus 0.56 (1.37) mg/dL and 61.50 (53.75)
versus 14.00 (28.00) mm/hour in patients with active and
inactive tuberculosis, respectively. ESR and CRP values
were elevated in patients with active tuberculosis as
compared with those of inactive cases (p< 0.001). There
was a significant correlation between ESR and CRP values in
patient group (rZ 63, p< 0.001). However, ESR or CRP
values did not correlate with sCD14 levels.
Discussion
There are a few studies investigating the role of
CD14-159C/T polymorphism in tuberculosis and theyFigure 3. Serum levels of sCD14 in active tuberculosis,
inactive tuberculosis and healthy controls. (The points repre-
sent mean values and the vertical lines represents plus/minus
one standard deviation).revealed conflicting results.3,17,18 A Mexican study evalu-
ating CD14-159C/T and TLR4 Asp299Gly polymorphisms in
tuberculosis claimed that the CD14-159 TT genotype was
a risk factor for development of pulmonary tuberculosis.17
Similarly, a study conducted in a Korean population re-
ported a significant association between this polymorphism
and tuberculosis.18 However, the study by Pacheco et al
failed to detect a significant association between CD14-
159C/T polymorphism and susceptibility to tuberculosis
and its clinical forms in a Colombian population.3 In this
present study, we investigated the association between
CD14-159C/T polymorphism and tuberculosis in a Turkish
population. There was no significant difference between
the genotype distribution of patients with tuberculosis and
controls. The percentage of TT homozygotes was similar in
both groups. We are unable to find an association between
the CD14 promoter polymorphism neither with the devel-
opment of tuberculosis nor with the severity of pulmonary
involvement. Many factors could contribute to these con-
flicting results reported in these studies. Our failure to
demonstrate an association between the CD14 promoter
polymorphism and tuberculosis may have been due to the
relatively small size of this study. Tuberculosis is a complex
disease and susceptibility is likely influenced by several
genetic and environmental factors.8,20 The racial and
environmental differences among the populations might
account for these conflicting results.
CD14 plays an important role in the induction of inflam-
matory responses evoked by a variety of microorganisms.1,10
Several studies have been conducted to show the impact of
the CD14 C-159T single nucleotide polymorphism on the risk
of infectious diseases. A multiple-center study by Gibot et al
provided suggestive evidence of an association between the
CD14 gene polymorphism and sepsis.11 They found that the
prevalence of the TT genotype was significantly higher in
patients with sepsis than in controls and that the mortality
rate in patients with the TT genotype was significantly
increased. Sutherland et al suggested that a single nucleo-
tide polymorphism (SNP) within the CD14 gene was associ-
ated with an increased prevalence of gram-negative
bacterial infections in critically ill adults.21 However, Agnese
et al and Jessen et al found no association between CD14 SNP
and gram-negative infection.22,23 Recently, a SNP within the
CD14 gene was demonstrated to be associated with the risk
of developing bacterial diarrhea.16 A possible relationship
between the CD14 C-159T polymorphism and several intra-
cellular infections such as brucellosis and chronic C pneu-
moniae infection, has also been implicated in different
populations.12,15
Tuberculosis is a broad-spectrum disease which may
involve both pulmonary and extrapulmonary locations.6 A
failure of some of the immune response genes involved in
controlling the dissemination of M tuberculosis from the
lung to other tissues may be responsible for the extrap-
ulmonary involvement. Our study included 25 cases of non-
HIV tuberculosis with different extrapulmonary involve-
ments, including pleural, lymph nodal, urogenital, osteo-
articular, and meningeal tuberculosis. There was no
significant difference in terms of CD14 genotype distribu-
tion between patients with pulmonary and extrapulmonary
tuberculosis and controls. The CD14 gene promoter poly-
morphism was also investigated in different clinical forms
162 E. Ayaslioglu et al.of tuberculosis by Pacheco et al3 and they found no asso-
ciation between the CD14 polymorphism and clinical forms
of extrapulmonary tuberculosis. The findings of these two
studies did not reveal any relationship between the CD14
gene promoter polymorphism and non-HIV extrapulmonary
tuberculosis. It is plausible that the CD14 gene promoter
polymorphism genotype does not influence the develop-
ment of extrapulmonary tuberculosis. Innate immune
mechanisms are undoubtedly essential in the initial phase
of the infection.24 There may be some defects in acquired
immune mechanisms and their molecules during the
development of extrapulmonary involvement.
The soluble form of CD14 is found in normal human serum
and is increased in several clinical conditions characterized
by local or systemic activation of monocytes/macro-
phages.23e30 Although the function of sCD14 in human
disease is not yet clarified, a potential pathogenic role has
been proposed for several infectious diseases. A vast
majority of evidence suggests that CD14 signaling is
a protective host response to intracellular bacterial patho-
gens such asM tuberculosis, and increased sCD14 levels were
documented in the sera and bronchoalveolar lavage fluid of
patients with active tuberculosis.25,29,30 Consistent with
previous reports, serum levels of sCD14 were found to be
significantly increased in active tuberculosis patients
compared with those with inactive tuberculosis and healthy
controls. These findings may implicate that CD14 signaling is
an important component of the initial anti-mycobacterial
host response. We also investigated the association
between the CD14 polymorphism and sCD14 levels. However,
we were unable to find any correlation between the CD14
polymorphism and the level of sCD14 in tuberculosis.
CD14 is a molecule with a wide range of functions. CD14-
induced activation of macrophages results in the release of
proinflammatory cytokines, such as tumor necrosis factor
(TNF)-alpha, interleukin (IL)-1 and IL-6.1,4 These inflamma-
tory cytokines lead to the production of acute phase reac-
tants. IL-6 induces sCD14 expression in liver cells and is
regardedas anacute phase protein.1 An increased sCD14 level
is not specific to infectious diseases; its concentration also
increases during several noninfectious inflammatory con-
ditions.26e28Although sCD14 levelswere significantly elevated
in our patients with active tuberculosis, the levels did not
correlate with CRP and ESR values. The lack of a positive
correlation is not surprising, given the fact that several other
accessory molecules are involved in CD14 signaling and
in the subsequent release of inflammatory cytokines.1,4,31,32
There are conflicting results regarding the association
between the CD14-159C/T polymorphism and tuberculosis
among different populations. The genotyping findings of
the present study do not support a role for the CD14-159C/T
polymorphism in the development of tuberculosis, at least
in the geographical region of central Anatolia. However,
significantly elevated serum sCD14 levels in patients with
active disease reflect the importance of the mononuclear
phagocytic system activation in tuberculosis and may
implicate that CD14 signaling is an important component of
the initial anti-mycobacterial host response. Since our
results are based on a relatively low number of subjects,
further large-scale studies are needed to demonstrate the
role of the CD14-159 gene polymorphism in susceptibility to
tuberculosis disease.Acknowledgment
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